Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Corporate Controller | March 31, 2025 | April 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,740 |
Ending reported balance
After 2025-03-31 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-03-31 · Exercise / conversion · Acquired 10,638 · Balance 33,971 Row 2 · 2025-03-31 · Tax withholding · Disposed 3,644 · Balance 30,327 F1: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2025-03-31 · Exercise / conversion · Acquired 8,503 · Balance 38,830 Row 4 · 2025-03-31 · Tax withholding · Disposed 2,913 · Balance 35,917 F1: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 5 · 2025-03-31 · Exercise / conversion · Acquired 4,294 · Balance 40,211 Row 6 · 2025-03-31 · Tax withholding · Disposed 1,471 · Balance 38,740 F1: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 40,295 |
Reported balance
After 2025-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-03-31 · Grant · Acquired 40,295 · Balance 40,295 F2: Each RSU converts into one share of Organon common stock. F3: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 21,276 |
Reported balance
After 2025-03-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-03-31 · Exercise / conversion · Disposed 10,638 · Balance 21,276 F2: Each RSU converts into one share of Organon common stock. F4: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,504 |
Reported balance
After 2025-03-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-03-31 · Exercise / conversion · Disposed 8,503 · Balance 8,504 F2: Each RSU converts into one share of Organon common stock. F5: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-03-31 · Exercise / conversion · Disposed 4,294 · Balance 0 F2: Each RSU converts into one share of Organon common stock. F6: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2: Each RSU converts into one share of Organon common stock.
F3: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.
F4: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.
F5: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.
F6: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 10 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F6 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 8,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 9 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,504 Underlying: Common Stock · 8,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F5 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 10,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 8 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,276 Underlying: Common Stock · 10,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F4 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 40,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · derivative · entry 7 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,295 Underlying: Common Stock · 40,295 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F3 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F3 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,471 | $14.51 | $21,344.21 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 6 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,740 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 5 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,913 | $14.51 | $42,267.63 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 4 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,917 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 8,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 3,644 | $14.51 | $52,874.44 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,327 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:35 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 10,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001861045-25-000002 · wk-form4_1743629704.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,231 | $20.35 | $25,050.85 |
DisclosureSEC source: 0001821825-24-000097 · wk-form4_1725568256.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,333 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000097 · wk-form4_1725568256.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,564 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:05 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000059 · wk-form4_1715112304.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:05 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 428 | $19.61 | $8,393.08 |
DisclosureSEC source: 0001821825-24-000059 · wk-form4_1715112304.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,970 Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:05 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000059 · wk-form4_1715112304.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 8,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000043 · wk-form4_1712184015.xml · derivative · entry 6 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,007 Underlying: Common Stock · 8,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000043 · wk-form4_1712184015.xml · derivative · entry 5 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,294 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,913 | $18.80 | $54,764.40 |
DisclosureSEC source: 0001821825-24-000043 · wk-form4_1712184015.xml · nonDerivative · entry 4 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,150 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 8,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000043 · wk-form4_1712184015.xml · nonDerivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,471 | $18.80 | $27,654.80 |
DisclosureSEC source: 0001821825-24-000043 · wk-form4_1712184015.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,560 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000043 · wk-form4_1712184015.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 31,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000021 · wk-form4_1712089273.xml · derivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,914 Underlying: Common Stock · 31,914 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000007 · wk-form4_1709328168.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,957 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,868 | $18.04 | $33,698.72 |
DisclosureSEC source: 0001821825-24-000007 · wk-form4_1709328168.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,737 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000007 · wk-form4_1709328168.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 16:16 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003170 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,871 shares Expires 2024-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of February 9, 2022, February 9, 2023, and February 9, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of February 9, 2022, February 9, 2023, and February 9, 2024, one-third of the RSUs vested. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 16:16 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 740 | $16.31 | $12,069.40 |
DisclosureSEC source: 0001209191-24-003170 · doc4.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,648 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 16:16 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003170 · doc4.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028096 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,248 Underlying: Common Stock · 1,246 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:42 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 427 | $24.24 | $10,350.48 |
DisclosureSEC source: 0001209191-23-028096 · doc4.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,517 Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028096 · doc4.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 25,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · derivative · entry 4 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,510 Underlying: Common Stock · 25,510 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,588 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,471 | $23.09 | $33,965.39 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,698 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023074 · doc4.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 18:04 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-018708 · tm236288-1_4seq1.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,869 Underlying: Common Stock · 1,869 shares Expires 2024-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On each of February 9, 2022 and February 9, 2023, one-third of the RSUs vested with the remaining RSUs to vest on February 9, 2024. F3 · derivative.expiration_date: On each of February 9, 2022 and February 9, 2023, one-third of the RSUs vested with the remaining RSUs to vest on February 9, 2024. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 18:04 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 740 | $29.68 | $21,963.20 |
DisclosureSEC source: 0001104659-23-018708 · tm236288-1_4seq1.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 18:04 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-018708 · tm236288-1_4seq1.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 04, 2022 Filed May 11, 2022 20:58 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-058956 · tm2215313-1_4seq1.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,246 Underlying: Common Stock · 1,246 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. F3 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. Read SEC document |
| May 04, 2022 Filed May 11, 2022 20:58 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 427 | $32.44 | $13,851.88 |
DisclosureSEC source: 0001104659-22-058956 · tm2215313-1_4seq1.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,746 Read SEC document |
| May 04, 2022 Filed May 11, 2022 20:58 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-058956 · tm2215313-1_4seq1.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:14 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 12,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042368 · tm2211465-11_4seq1.xml · derivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,882 Underlying: Common Stock · 12,882 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,869 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005697 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,740 Underlying: Common Stock · 1,869 shares Expires 2024-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On June 2, 2021 in connection with the separation of Organon from Merck & Co., Inc., the restricted stock unit award was converted into a restricted stock unit award with 5,609 shares of Organon common stock underlying such award. These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments. The first installment vested and has been distributed on February 9, 2022. The remaining installments will vest and be distributed on each of February 9, 2023 and February 9, 2024. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 745 | $33.75 | $25,143.75 |
DisclosureSEC source: 0000899243-22-005697 · doc4.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927 Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:10 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,869 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005697 · doc4.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:04 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033663 · doc4.xml · derivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 28,996 | $0.00 Strike: $36.11 | $0.00 |
DisclosureSEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 5 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,996 Underlying: Common Stock · 28,996 shares Expires 2031-05-03 F8 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F9 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 4,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 4 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,957 Underlying: Common Stock · 4,957 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 3,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,740 Underlying: Common Stock · 3,740 shares Expires 2024-05-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 5,609 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,609 Underlying: Common Stock · 5,609 shares Expires 2024-02-09 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on February 9, 2022, February 9, 2023 and February 9, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.